Meridian Wealth Management LLC raised its stake in shares of SPDR S&P Biotech (NYSEARCA:XBI) by 25.4% during the 3rd quarter, according to the company in its most recent filing with the SEC. The firm owned 7,028 shares of the exchange traded fund’s stock after purchasing an additional 1,425 shares during the quarter. Meridian Wealth Management LLC’s holdings in SPDR S&P Biotech were worth $608,000 as of its most recent filing with the SEC.

Several other large investors also recently bought and sold shares of the company. Quantitative Investment Management LLC increased its holdings in shares of SPDR S&P Biotech by 642.3% during the 2nd quarter. Quantitative Investment Management LLC now owns 1,451,998 shares of the exchange traded fund’s stock worth $112,065,000 after purchasing an additional 1,256,398 shares during the period. Raymond James Financial Services Advisors Inc. increased its holdings in shares of SPDR S&P Biotech by 25.8% during the 3rd quarter. Raymond James Financial Services Advisors Inc. now owns 302,809 shares of the exchange traded fund’s stock worth $26,214,000 after purchasing an additional 62,100 shares during the period. Ardsley Advisory Partners increased its holdings in shares of SPDR S&P Biotech by 25.7% during the 2nd quarter. Ardsley Advisory Partners now owns 276,000 shares of the exchange traded fund’s stock worth $21,295,000 after purchasing an additional 56,500 shares during the period. FMR LLC boosted its position in shares of SPDR S&P Biotech by 6.2% during the 2nd quarter. FMR LLC now owns 191,702 shares of the exchange traded fund’s stock valued at $14,796,000 after acquiring an additional 11,241 shares in the last quarter. Finally, Papp L Roy & Associates boosted its position in shares of SPDR S&P Biotech by 3.1% during the 2nd quarter. Papp L Roy & Associates now owns 187,538 shares of the exchange traded fund’s stock valued at $14,474,000 after acquiring an additional 5,648 shares in the last quarter.

Shares of SPDR S&P Biotech (NYSEARCA:XBI) traded up $1.70 during trading on Friday, hitting $85.60. 1,020,000 shares of the stock traded hands. SPDR S&P Biotech has a 1-year low of $53.45 and a 1-year high of $88.98.

ILLEGAL ACTIVITY NOTICE: This report was originally published by Watch List News and is the sole property of of Watch List News. If you are reading this report on another domain, it was illegally stolen and republished in violation of international copyright & trademark laws. The legal version of this report can be viewed at https://www.watchlistnews.com/meridian-wealth-management-llc-boosts-stake-in-spdr-sp-biotech-xbi/1680787.html.

SPDR S&P Biotech Company Profile

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.

Institutional Ownership by Quarter for SPDR S&P Biotech (NYSEARCA:XBI)

Receive News & Ratings for SPDR S&P Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech and related companies with Analyst Ratings Network's FREE daily email newsletter.